Results for endoftalmitisa translation from Slovenian to English

zdravljenju endoftalmitisa
management of endophthalmitis

poleg tega je treba bolnike dva tedna po injekciji natančno nadzirati glede endoftalmitisa.
moreover patients should be closely monitored for endophthalmitis in the two weeks following the injection.

poleg tega je treba bolnike dva tedna po injekciji natančno nadzirati glede krvavitve v steklovino in endoftalmitisa.
moreover patients should be closely monitored for vitreous haemorrhage and endophthalmitis in the two weeks following the injection.

ključne znake in simptome resnih neželenih učinkov tj. endoftalmitisa, povišanega intraokularnega tlaka, zatrganja pigmentnega epitelija mrežnice in katarakte
key signs and symptoms of serious adverse events including endophthalmitis, intraocular pressure increased, retinal pigment epithelial tear and cataract

postopke intravitrealnega injiciranja spremlja tveganje za endoftalmitis; v kliničnih preskušanjih zdravila macugen je bila pogostnost endoftalmitisa 0, 1% na injekcijo.
intravitreal injection procedures are associated with a risk of endophthalmitis; in macugen clinical trials, the incidence of endophthalmitis was 0.1% per injection.

a) intravitrealnem postopku, kot so ga opravljali v ključnih kliničnih študijah b) sterilnih tehnikah za zmanjševanje tveganja okužbe na najmanjšo mogočo mero c) uporabi antibiotikov d) uporabi povidon jodida e) opravljanju čiščenja vek f) uporabi anestetika za preprečevanje neprijetnosti postopka za bolnika g) tehnikah intravitrealnega injiciranja h) urejanju intraokularnega tlaka (iop – » intraocular pressure «) i) zdravljenju endoftalmitisa j) poznavanju dejavnikov tveganja za nastanek endoftalmitisa k) prijavljanju resnih neželenih dogodkov • izobraževalni program za bolnike, katerega namen je zmanjševanje tveganj na najmanjšo mogočo mero in podpora varni in učinkoviti uporabi zdravila.
b) sterile techniques to minimize risk of infection c) use of antibiotics d) use of povidone iodine e) performing lid scrubs f) use of anesthetic to ensure patient comfort g) techniques for the intravitreal injection h) management of intraocular pressure (iop) i) management of endophthalmitis j) understanding the risk factors involved in developing endophthalmitis k) reporting of serious adverse events • an educational plan for patients which is aimed at risk minimisation and to support safe and effective use for the product.